SuperworthBiotech stocks with the highest free cash flow yield
Free cash flow over the last twelve months as a share of market value. As of .
- Ranked
- 18
- of 146 biotech stocks we cover
- Median
- 3.4%
- Highest
- 19.1%
- BCRX
- Range
- 1.1% to 19.1%
median 3.4%
1.1%19.1%
| # | Company | FCF yield | PE | Revenue growth (TTM) | Market cap |
|---|---|---|---|---|---|
| 1 | BCRXBiocryst Pharmaceuticals | 19.1% | n/m | +68.7% | $2B |
| 2 | INCYIncyte | 8.2% | 14.7× | +26.9% | $23.5B |
| 3 | EXELExelixis | 7.3% | 20.3× | +9.2% | $16B |
| 4 | NBIXNeurocrine Biosciences | 6.0% | 20.9× | +34.4% | $14.5B |
| 5 | HALOHalozyme Therapeutics | 5.7% | 37.5× | +41.2% | $14.3B |
| 6 | ADMAAdma Biologics | 4.9% | 15.3× | +8.0% | $2.4B |
| 7 | REGNRegeneron Pharmaceuticals | 4.5% | 19.9× | +9.3% | $82.9B |
| 8 | UTHRUnited Therapeutics | 4.3% | 21.0× | +2.5% | $25.2B |
| 9 | PLXProtalix BioTherapeutics | 3.7% | 11.1× | +30.1% | $205.5M |
| 10 | ONCBeOne Medicines | 3.1% | 67.6× | +34.3% | $42.9B |
| 11 | VRTXVertex Pharmaceuticals | 2.9% | 30.5× | +10.2% | $132.8B |
| 12 | VCELVericel | 2.8% | 92.5× | +23.0% | $2.2B |
| 13 | KRYSKrystal Biotech | 2.8% | 39.0× | +22.6% | $9.2B |
| 14 | ALNYAlnylam Pharmaceuticals | 2.6% | 37.8× | +95.1% | $30B |
| 15 | TECHBIO-TECHNE | 2.3% | 63.1× | −0.4% | $11.4B |
| 16 | TARSTarsus Pharmaceuticals | 1.9% | n/m | +105.2% | $3B |
| 17 | MGTXMeiraGTx | 1.2% | 13.0× | n/m | $884.6M |
| 18 | RGENRepligen | 1.1% | 242× | +16.5% | $10B |
Not ranked: 76 with no positive free cash flow, 29 with not a meaningful number. 23 companies whose data behind this number has a caveat are left out until it is checked.
A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.